Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 4
Testing once-daily eliglustat in stable adults with Gaucher disease type 1
Tests once-daily eliglustat in stable adults with Gaucher disease type 1.
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- ONCE: Once daily eliglustat in stable CYP2D6 intermediate and extensive metabolizers with Gaucher disease type 1
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 7 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 1 Nov 2027
- Type of study
- Interventional
- Record updated
- 22 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Gaucher disease type 1 who are stable on eliglustat 84 mg twice a day and are CYP2D6 intermediate or extensive metabolizers. It tests a switch to once a day.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Confirmed Gaucher disease type 1 with an indication for therapy, and stable disease: hemoglobin ≥ 9.7 g/dL, platelets ≥100x109/L, spleen volume < 10 MN (if present), liver volume < 1.5 MN, and no bone crisis or symptomatic bone disease in the past 12 months.
- Earlier treatment
- Treated with eliglustat 84 mg twice a day (BID) for ≥ 6 months.
- Biomarker or test result
- CYP2D6 intermediate or extensive metabolizer status.
Main reasons for not taking part
- CYP2D6 poor metabolizer status
- Active malignancy or an uncontrolled medical condition that may affect the results or add risk
- Pregnancy or breastfeeding
- Use of strong CYP2D6 or CYP3A inhibitors or inducers
- Not taking current treatment as directed, or unable to follow study procedures
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults (≥ 18 years) with confirmed GD1 and indication for therapy, as determined by the expert center multidisciplinary team
- CYP2D6 intermediate or extensive metabolizer status
- Treated with eliglustat 84 mg BID for ≥ 6 months
- Stable disease, defined as: o Hemoglobin ≥ 9.7 g/dL (women & men) o Platelets ≥100x109/L o Spleen volume < 10 MN (if present) o Liver volume < 1.5 MN o No bone crisis or symptomatic bone disease in the past 12 months
Who cannot take part
- Use of strong CYP2D6 or CYP3A inhibitors or inducers, as defined in the eliglustat SmPC
- Non-adherence to current therapy or inability to comply with study procedures
- Participation in another interventional trial within 3 months before enrolment
- Active malignancy or uncontrolled medical condition that may confound study outcomes or pose additional risk
- CYP2D6 poor metabolizer (PM) status
- Pregnancy or lactation
Where in Netherlands
- Amsterdam UMC Research B.V.Amsterdam, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To evaluate whether switching from 84 mg BID to 84 mg QD eliglustat maintains clinical stability over a 12-month period in adult GD1 patients who are CYP2D6 IM/EM and clinically stable on long-term BID therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- ONCE: Once daily eliglustat in stable CYP2D6 intermediate and extensive metabolizers with Gaucher disease type 1
- Plain-language title
- Testing once-daily eliglustat in stable adults with Gaucher disease type 1Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 22 October 2026